150
Participants
Start Date
March 10, 2025
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2026
Fezolinetant
oral
Placebo
oral
RECRUITING
Beijing Hospital, Beijing
RECRUITING
Capital Medical University (CMU) - Beijing Shijitan Hospital, Beijing
RECRUITING
Capital Medical University - Beijing Obstetrics and Gynecology Hospital, Beijing
RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
Guangzhou Medical University - The Third Affiliated Hospital, Guangzhou
RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
RECRUITING
Peking University Shenzhen Hospital, Shenzhen
RECRUITING
Shenzhen Maternal & Child Health Hospital, Shenzhen
RECRUITING
Guangxi Medical University (GXMU) - Liuzhou Renmin Hospital, Liuzhou
RECRUITING
Liuzhou Worker's Hospital, Liuzhou
RECRUITING
Guangzhou Medical University - The Third Affiliated Hospital, Guangzhou
RECRUITING
Hainan Women and Children's Medical Center, Haikou
RECRUITING
The second Hospital of Hebei Medical University, Shijiazhuang
RECRUITING
Hunan Provincial Maternal and Child Health Care Hospital, Changsha
RECRUITING
Xiangya Hospital, Central South University, Zhuzhou
RECRUITING
Nanjing First Hospital, Nanjing
RECRUITING
Southeast University, ZhongDa Hospital, Nanjing
RECRUITING
Jiangxi Maternal and Child Health Hospital, Nanchang
RECRUITING
Jilin Province FAW General Hospital, Changchun
RECRUITING
Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan
RECRUITING
Shandong Provincial Hospital, Jinan
RECRUITING
Shanghai First Maternity and Infant Hospital, Shanghai
RECRUITING
Shanxi Woman and Children Hospital, Taiyuan
RECRUITING
The First hospital of Shanxi Medical University, Taiyuan
RECRUITING
Chengdu Women's and Children's Central Hospital, Chengdu
RECRUITING
The Second Hospital of Tianjin Medical University, Tianjin
RECRUITING
Hangzhou First People's Hospital, Hangzhou
Astellas Pharma Global Development, Inc.
INDUSTRY